N-[[18-[2-[4-(isopropyl)thiazol-2-yl]-7-methoxyquinolin-4-yloxy]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-4-yl]carbonyl](cyclopropyl)sulfonamide → N-[18-[7-methoxy-2-(thiazol-2-yl)quinolin-4-yloxy]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carbonyl](cyclopropyl)-sulfonamide

HRID 1669559Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1669559
COC1C=C2C(C(OC3CC4N(C(=O)CCCCCCC=CC5C(C(O)=O)(NC4=O)C5)C3)=CC(C3SC=CN=3)=N2)=CC=1.C([C:46]1[N:47]=[C:48]([C:51]2[CH:60]=[C:59]([O:61][CH:62]3[CH2:80][CH:79]4[N:64]([C:65](=[O:91])[CH2:66][CH2:67][CH2:68][CH2:69][CH2:70][CH2:71][CH:72]=[CH:73][CH:74]5[C:76]([C:82]([NH:84][S:85]([CH:88]6[CH2:90][CH2:89]6)(=[O:87])=[O:86])=[O:83])([NH:77][C:78]4=[O:81])[CH2:75]5)[CH2:63]3)[C:58]3[C:53](=[CH:54][C:55]([O:92][CH3:93])=[CH:56][CH:57]=3)[N:52]=2)[S:49][CH:50]=1)(C)C>>[CH3:93][O:92][C:55]1[CH:54]=[C:53]2[C:58]([C:59]([O:61][CH:62]3[CH2:80][CH:79]4[N:64]([C:65](=[O:91])[CH2:66][CH2:67][CH2:68][CH2:69][CH2:70][CH2:71][CH:72]=[CH:73][CH:74]5[C:76]([C:82]([NH:84][S:85]([CH:88]6[CH2:90][CH2:89]6)(=[O:86])=[O:87])=[O:83])([NH:77][C:78]4=[O:81])[CH2:75]5)[CH2:63]3)=[CH:60][C:51]([C:48]3[S:49][CH:50]=[CH:46][N:47]=3)=[N:52]2)=[CH:57][CH:56]=1

Komponenten

3

Edukt 2

HCID 67318810N-[[18-[2-[4-(isopropyl)thiazol-2-yl]-7-methoxyquinolin-4-yloxy]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-4-yl]carbonyl](cyclopropyl)sulfonamideHCID 6732021718-[7-Methoxy-2-(thiazol-2-yl)quinolin-4-yloxy]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid

Produkt 1

HCID 67319286N-[18-[7-methoxy-2-(thiazol-2-yl)quinolin-4-yloxy]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carbonyl](cyclopropyl)-sulfonamide

Versuchsvorschrift

The title compound was prepared from 18-[7-methoxy-2-(thiazol-2-yl)quinolin-4-yloxy]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid (31) following the procedure reported for synthesis of N-[[18-[2-[4-(isopropyl)thiazol-2-yl]-7-methoxyquinolin-4-yloxy]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-4-yl]carbonyl](cyclopropyl)sulfonamide 11: m/z=694 (M+H)+. 1H NMR (CDCl3): 0.90-1.5 (m, 9H), 1.6-1.8 (m, 8H), 2.1-2.4 (m, 2H), 2.45-2.55 (m, 2H), 2.6-2.7 (m, 1H), 2.9-3 (m, 1H), 3.9 (s, 3H), 4.12 (dd, J=11.6 Hz, J=3.7 Hz, 1H), 5.1 (t, J=7.9 Hz, 1H), 5.00 (t, J=9 Hz, 1H), 5.48 (t, J=2.9 Hz, 1H), 5.7 (dd, J=18.2 Hz, J=8.8 Hz, 1H), 7 (br s, 1H), 7.15 (dd, J=9.1 Hz, J=2.4 Hz, 1H), 7.4 (d, J=2.4 Hz, 1H), 7.5 (d, J=3.2 Hz, 1H), 7.59 (s, 1H), 7.9 (d, J=3.2 Hz, 1H), 7.9 (d, J=9.1 Hz, 1H), 10.3 (br s, 1H).

Quellen und Nachweise

ORD-Eintrag
ord-0c8f2ca6b8114d87a9aaa47669e5fe06
Quelldatensatz
uspto-grants-2011_08
Patentnummer
US07989471B2

Notizen zur Reaktion

Wird geladen…